File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Thymosin-α1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase

TitleThymosin-α1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase
Authors
KeywordsFamciclovir
HBV
Immune tolerant
Thymosin-α1
Issue Date2002
Citation
Journal Of Viral Hepatitis, 2002, v. 9 n. 4, p. 280-287 How to Cite?
AbstractWe examined whether combination therapy with thymosin-α1 and famciclovir would induce hepatitis B e antigen seroconversion in patients with chronic hepatitis B infection in the immune-tolerant phase without inducing significant hepatic necro-inflammation. We studied 32 hepatitis B e antigen positive patients in the immune-tolerant phase of infection, treated with 26-weeks combination therapy of famciclovir and thymosin-α1 (group 1). Thirty-two patients who received 26-weeks famciclovir monotherapy (group 2) and another 32 patients who received no treatment (group 3), served as controls. Peripheral blood mononuclear cell proliferation and cytokine secretion in response to recombinant HBV core and surface antigen and serial serum HBV-DNA, were assayed. No significant difference in adverse events were observed among the three groups. By week 26, the median reduction in group 1 (0.94 log 10 copies/mL) was greater than group 2 (0.70 log 10 copies/mL, P < 0.001). Five (15.6%) patients in group 1 at 52 weeks (median range 13-78 weeks) and none in group 2 or 3 experienced hepatitis B e antigen seroconversion (P = 0.053). Sustained serological clearance of hepatitis B e antigen was associated with activation of CD4 positive HBV-specific T-cell reactivity and were of T-helper 1. Hence combination therapy with immunomodulatory agents and nucleoside analogues should be explored.
Persistent Identifierhttp://hdl.handle.net/10722/167738
ISSN
2014 Impact Factor: 3.909
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLau, GKKen_HK
dc.contributor.authorNanji, Aen_HK
dc.contributor.authorHou, Jen_HK
dc.contributor.authorFong, DYTen_HK
dc.contributor.authorAu, WSen_HK
dc.contributor.authorYuen, STen_HK
dc.contributor.authorLin, Men_HK
dc.contributor.authorKung, HFen_HK
dc.contributor.authorLam, SKen_HK
dc.date.accessioned2012-10-08T03:10:46Z-
dc.date.available2012-10-08T03:10:46Z-
dc.date.issued2002en_HK
dc.identifier.citationJournal Of Viral Hepatitis, 2002, v. 9 n. 4, p. 280-287en_HK
dc.identifier.issn1352-0504en_HK
dc.identifier.urihttp://hdl.handle.net/10722/167738-
dc.description.abstractWe examined whether combination therapy with thymosin-α1 and famciclovir would induce hepatitis B e antigen seroconversion in patients with chronic hepatitis B infection in the immune-tolerant phase without inducing significant hepatic necro-inflammation. We studied 32 hepatitis B e antigen positive patients in the immune-tolerant phase of infection, treated with 26-weeks combination therapy of famciclovir and thymosin-α1 (group 1). Thirty-two patients who received 26-weeks famciclovir monotherapy (group 2) and another 32 patients who received no treatment (group 3), served as controls. Peripheral blood mononuclear cell proliferation and cytokine secretion in response to recombinant HBV core and surface antigen and serial serum HBV-DNA, were assayed. No significant difference in adverse events were observed among the three groups. By week 26, the median reduction in group 1 (0.94 log 10 copies/mL) was greater than group 2 (0.70 log 10 copies/mL, P < 0.001). Five (15.6%) patients in group 1 at 52 weeks (median range 13-78 weeks) and none in group 2 or 3 experienced hepatitis B e antigen seroconversion (P = 0.053). Sustained serological clearance of hepatitis B e antigen was associated with activation of CD4 positive HBV-specific T-cell reactivity and were of T-helper 1. Hence combination therapy with immunomodulatory agents and nucleoside analogues should be explored.en_HK
dc.languageengen_US
dc.relation.ispartofJournal of Viral Hepatitisen_HK
dc.subjectFamcicloviren_HK
dc.subjectHBVen_HK
dc.subjectImmune toleranten_HK
dc.subjectThymosin-α1en_HK
dc.titleThymosin-α1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phaseen_HK
dc.typeArticleen_HK
dc.identifier.emailFong, DYT: dytfong@hku.hken_HK
dc.identifier.emailLin, M: mcllin@hkucc.hku.hken_HK
dc.identifier.authorityFong, DYT=rp00253en_HK
dc.identifier.authorityLin, M=rp00746en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1046/j.1365-2893.2002.00361.xen_HK
dc.identifier.pmid12081605-
dc.identifier.scopuseid_2-s2.0-0036633685en_HK
dc.identifier.hkuros78774-
dc.identifier.hkuros67333-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036633685&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume9en_HK
dc.identifier.issue4en_HK
dc.identifier.spage280en_HK
dc.identifier.epage287en_HK
dc.identifier.isiWOS:000176447100005-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLau, GKK=7102301257en_HK
dc.identifier.scopusauthoridNanji, A=35885060300en_HK
dc.identifier.scopusauthoridHou, J=7401966390en_HK
dc.identifier.scopusauthoridFong, DYT=35261710300en_HK
dc.identifier.scopusauthoridAu, WS=7202383097en_HK
dc.identifier.scopusauthoridYuen, ST=7103160927en_HK
dc.identifier.scopusauthoridLin, M=7404816359en_HK
dc.identifier.scopusauthoridKung, HF=7402514190en_HK
dc.identifier.scopusauthoridLam, SK=7402279473en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats